DMAC DiaMedica Therapeutics Inc

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders, today announced that Rick Pauls, its President and CEO will be participating at Lake Street Capital Market’s 7th Annual Best Ideas Growth (BIG7) Conference in New York, on September 14, 2023. Management will conduct one-on-one meetings with investors during the conference.

To receive additional information or to schedule a one-on-one meeting, please contact your Lake Street Capital Markets representative.

About DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. DiaMedica’s lead candidate DM199 is the first pharmaceutically active and clinically studied recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of acute ischemic stroke and other vascular diseases. For more information visit our website at www.diamedica.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230906375201/en/

Scott Kellen Chief Financial Officer Phone: (763) 496-5118 skellen@diamedica.com

Paul Papi Corporate Communications Phone: 617-899-5941 ppapi@diamedica.com

DiaMedica Therapeutics (NASDAQ:DMAC)
Gráfica de Acción Histórica
De Abr 2024 a May 2024

DiaMedica Therapeutics (NASDAQ:DMAC)
Gráfica de Acción Histórica
De May 2023 a May 2024